The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: A meta-analysis

European Journal of Cancer Prevention

Volumn 26, Issue 1, 2017, Pages 78-85

  Song, Taejong ^a   Choi, Chel Hun ^b   Kim, Mi Kyoung ^c   Kim, Mi La ^c   Yun, Bo Seong ^c   Seong, Seok Ju ^c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c CHA University   (South Korea)

Author keywords

angiotensin receptor blockers; angiotensin converting enzyme inhibitors; cancer; mortality; survival

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FOSINOPRIL; IMIDAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; MOEXIPRIL; OLMESARTAN; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TELMISARTAN; TEMOCAPRIL; TRANDOLAPRIL; VALSARTAN;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; COLORECTAL CANCER; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG EFFECT; EMBASE; EVIDENCE BASED PRACTICE; HUMAN; LIVER CELL CARCINOMA; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SYSTEMATIC REVIEW; URINARY TRACT CANCER; MORTALITY; NEOPLASM; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84966290903     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000269     Document Type: Article

References (41)

1. ADA. (2009). Standards of medical care in diabetes -2009. Diabetes Care 32 (Suppl 1): S13-S61
2. Anandanadesan R, Gong Q, Chipitsyna G, Witkiewicz A, Yeo CJ, Arafat HA. (2008). Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling. J Gastrointest Surg 12: 57-66
3. Arrieta O, Guevara P, Escobar E, García-Navarrete R, Pineda B, Sotelo J. (2005). Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 92: 1247-1252
4. Attoub S, Gaben AM, Al-Salam S, Al Sultan MA, John A, Nicholls MG, et al. (2008). Captopril as a potential inhibitor of lung tumor growth and metastasis. Ann N Y Acad Sci 1138: 65-72
5. Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, Tester W. (2011). Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest 29: 585-593
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. (2003). The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289: 2560-2572
7. Deshayes F, Nahmias C. (2005). Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16: 293-299
8. Escobar E, Rodríguez-Reyna TS, Arrieta O, Sotelo J. (2004). Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2: 385-399
9. Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M. (2002). Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 294: 441-447
10. Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M, Majima M. (2005). Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 26: 271-279
11. Furlan AD, Pennick V, Bombardier C, van Tulder M. (2009). 2009 Updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976) 34: 1929-1941
12. Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW. (2011). Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 129: 549-556
13. Greco S, Muscella A, Elia MG, Salvatore P, Storelli C, Mazzotta A, et al. (2003). Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol 196: 370-377
14. Heinzerling JH, Anthony T, Livingston EH, Huerta S. (2007). Predictors of distant metastasis and mortality in patients with stage II colorectal cancer. Am Surg 73: 230-238
15. Higgins JP, Green S. (2008). Handbook for systematic reviews of interventions. New York, NY: John Wiley and Sons
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. (2003). Measuring inconsistency in meta-analyses. BMJ 327: 557-560
17. Hori K, Saito S, Takahashi H, Sato H, Maeda H, Sato Y. (2000). Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride. Jpn J Cancer Res 91: 261-269
18. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. (2005). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: e154-e235
19. Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, et al. (2011). Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer 47: 1955-1961
20. Maeda H. (2010). Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 21: 797-802
21. Maeda H. (2012). Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumorselective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci 88: 53-71
22. Maeda H, Sawa T, Konno T. (2001). Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74 (1-3): 47-61
23. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, et al. (2011). Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29: 2645-2652
24. Miyajima A, Kosaka T, Asano T, Asano T, Seta K, Kawai T, Hayakawa M. (2002). Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62: 4176-4179
25. Moskowitz DW, Johnson FE. (2004). The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem 4: 1433-1454
26. Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, et al. (2010). Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer 103: 1644-1648
27. Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C. (2007). Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol 22: 577-584
28. Noguchi A, Takahashi T, Yamaguchi T, Kitamura K, Noguchi A, Tsurumi H, et al. (1992). Enhanced tumor localization of monoclonal antibody by treatment with kininase II inhibitor and angiotensin II. Jpn J Cancer Res 83: 240-243
29. Noguchi R, Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K, et al. (2003). Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 9 (Pt 1): 6038-6045
30. Parmar MK, Torri V, Stewart L. (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834
31. Redondo-Müller MA, Stevanovic-Walker M, Barker S, Puddefoot JR, Vinson GP. (2008). Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor. Endocr Relat Cancer 15: 277-288
32. Ronquist G, Frithz G, Wang YH, Lindeborg T. (2009). Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer. Scand J Urol Nephrol 43: 32-36
33. Tanaka N, Miyajima A, Kikuchi E, Matsumoto K, Hagiwara M, Ide H, et al. (2012). Prognostic impact of renin-angiotensin system blockade in localised uppertract urothelial carcinoma. Br J Cancer 106: 290-296
34. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. (2007). Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16
35. Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, et al. (2003). Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2: 1139-1147
36. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, et al. (1996). Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98: 671-679
37. Walther T, Menrad A, Orzechowski HD, Siemeister G, Paul M, Schirner M. (2003). Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J 17: 2061-2067
38. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. (2009). Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 135: 1429-1435
39. Yasumatsu R, Nakashima T, Masuda M, Ito A, Kuratomi Y, Nakagawa T, Komune S. (2004). Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol 130: 567-573
40. Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y, Yamazaki M, et al. (2011). Combination of branched-chain amino acids and angiotensinconverting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial. Oncol Rep 26: 1547-1553
41. Yuge K, Miyajima A, Tanaka N, Shirotake S, Kosaka T, Kikuchi E, Oya M. (2012). Prognostic value of renin-angiotensin system blockade in non-muscleinvasive bladder cancer. Ann Surg Oncol 19: 3987-3993